Sirigen completes financing for HSF diagnostic technology

Sirigen Group has completed two financing rounds totalling £3.83m and led by a syndicate of new investors comprising IQ Capital, NESTA (National Endowment for Science, Technology and the Arts) and YFM Private Equity alongside existing investors, Seraphim Capital and Oxford Capital Partners.

The financing will be used to commercialise Sirigen’s High Sensitivity Fluorescence (HSF) technology, designed to significantly boost the performance of in-vitro diagnostic tools.